Journal
TRANSLATIONAL STROKE RESEARCH
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s12975-022-01100-w
Keywords
Ischemic stroke; Cerebral blood flow; Collateral blood flow; Adjunctive therapy
Categories
Ask authors/readers for more resources
Ischemic stroke is a significant burden on the global economy and public health. Many stroke patients do not have access to available endovascular therapies, and robust collateral flow is important for successful treatment and outcomes. This review explores potential therapies for enhancing cerebral blood flow during acute ischemic stroke and discusses the steps required for further research.
Ischemic stroke presents a major global economic and public health burden. Although recent advances in available endovascular therapies show improved functional outcome, a good number of stroke patients are either ineligible or do not have access to these treatments. Also, robust collateral flow during acute ischemic stroke independently predicts the success of endovascular therapies and the outcome of stroke. Hence, adjunctive therapies for cerebral blood flow (CBF) enhancement are urgently needed. A very clear overview of the pial collaterals and the role of genetics are presented in this review. We review available evidence and advancement for potential therapies aimed at improving CBF during acute ischemic stroke. We identified heme-free soluble guanylate cyclase activators; Sanguinate, remote ischemic perconditioning; Fasudil, S1P agonists; and stimulation of the sphenopalatine ganglion as promising potential CBF-enhancing therapeutics requiring further investigation. Additionally, we outline and discuss the critical steps required to advance research strategies for clinically translatable CBF-enhancing agents in the context of acute ischemic stroke models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available